Chemokines and malaria infection

Current Immunology Reviews

Volumn 2, Issue 4, 2006, Pages 331-344

  Miu, Jenny ^a   Mitchell, Andrew J ^a   Ball, Helen J ^a   Hunt, Nicholas H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemokines; Immunopathology; Leukocytes; Malaria

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CYTOKINE; EOTAXIN; INTERLEUKIN 8; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; STROMAL CELL DERIVED FACTOR 1;

AFRICA; BRAIN MALARIA; CELL INFILTRATION; CELLULAR IMMUNITY; CLINICAL FEATURE; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INCIDENCE; LEUKOCYTE; LOW BIRTH WEIGHT; MALARIA; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PLACENTA; PLASMODIUM FALCIPARUM; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SPLEEN;

EID: 33750693726     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573395510602040331     Document Type: Review

References (205)

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434: 214-7.
2. WHO. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94 Suppl 1: S1-90.
3. Wellems TE. Plasmodium chloroquine resistance and the search for a replacement antimalarial drug. Science 2002; 298: 124-6.
4. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-92.
5. Phillips RS. Current status of malaria and potential for control. Clin Microbiol Rev 2001; 14: 208-26.
6. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002; 415: 680-5.
7. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurology 2005; 4: 827-40.
8. Holding PA, Stevenson J, Peshu N, Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999; 93: 529-34.
9. Nosten F, Rogerson SJ, Beeson JG, et al. Malaria in pregnancy and the endemicity spectrum: what can we learn? Trends Parasitol 2004; 20: 425-32.
10. Combes V, de Souza EB, Renia L, Hunt NH, Gran GE. Cerebral Malaria: Which parasite? Which model? Drug Discovery Today: Disease Models 2005; 2: 141-7.
11. de Souza JB, Riley EM. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 2002; 4: 291-300.
12. Engwerda C, Belnoue E, Gruner AC, Renia L. Experimental models of cerebral malaria. Curr Top Microbiol Immunol 2005; 297: 103-43.
13. Hunt NH, Grau GE. Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria. Trends Immunol 2003; 24: 491-9.
14. Neill AL, Hunt NH. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology 1992; 105: 165-75.
15. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA 2005; 162: 11468-73.
16. Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB. Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. Infect Immun 2000; 68: 5364-76.
17. Jennings VM, Actor JK, Lal AA, Hunter RL. Cytokine profile suggesting that murine cerebral malaria is an encephalitis. Infect Immun 1997; 65: 4883-7.
18. Coltel N, Combes V, Hunt NH, Grau GE. Cerebral malaria- a neurovascular pathology with many riddles still to be solved. Curr Neurovasc Res 2004; 1: 91-110.
19. Patnaik JK, Das BS, Mishra SK, et al Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. Am J Trop Med Hyg 1994; 51: 642-7.
20. Porta J, Carota A, Pizzolato GP, et al. Immunopathological changes in human cerebral malaria. Clin Neuropathol 1993; 12: 142-6.
21. Li C, Seixas E, Langhorne J. Rodent malarias: the mouse as a model for understanding immune responses and pathology induced by the erythrocytic stages of the parasite. Med Microbiol Imumnol (Berl) 2001; 189: 115-26.
22. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-76.
23. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54: 227-9.
24. Thorpe R. Chemokine/chemokine receptor nomenclature. Cytokine 2003; 21: 48-9.
25. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 75-84.
26. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020-34.
27. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immumol 2000; 18: 593-620.
28. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998; 95: 9448-53.
29. Nagasawa T. A chemokine, SDF-1/PBSF, and its receptor, CXC chemokine receptor 4, as mediators of hematopoiesis. Int J Hematol 2000; 72: 408-11.
30. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393: 595-9.
31. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
32. Kuschert GS, Conlin F, Power CA, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999; 38: 12959-68.
33. Andjelkovic AV, Kerkovich D, Shanley J, Pulliam L, Pachter JS. Expression of binding sites for beta chemokines on human astrocytes. Glia 1999; 28: 225-35.
34. Dzenko KA, Andjelkovic AV, Kuziel WA, Pachter JS. The chemokine receptor CCR2 mediates the binding and internalization of monocyte chemoattractant protein-1 along brain microvessels. J Neurosci 2001; 21: 9214-23.
35. Middleton J, Neil S, Wintle J, et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997; 91: 385-95.
36. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002; 100: 3853-60.
37. Alon R, Grabovsky V, Feigelson S. Chemokine induction of integrin adhesiveness on rolling and arrested leukocytes local signaling events or global stepwise activation? Microcirculation 2003; 10: 297-311.
38. Campbell JJ, Hedrick J, Zlotnik A, et al. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998; 279: 381-4.
39. Grabovsky V, Feigelson S, Chen C, et al. Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J Exp Med 2000; 192: 495-506.
40. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999; 398: 718-23.
41. Piali L, Weber C, LaRosa G, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol 1998; 28: 961-72.
42. Quandt J, Dorovini-Zis K. The beta chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J Neuropathol Exp Neurol 2004; 63: 350-62.
43. Dufour JH, Dziejman M, Liu MT, et al. IFN-(gamma)-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-204.
44. Whiting D, Hsieh G, Yun JJ, et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol 2004; 172: 7417-24.
45. Hadley TJ, Peiper SC. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood 1997; 89: 3077-91.
46. Horuk R, Chitnis CE, Darbonne WC, et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993; 261: 1182-4.
47. Hadley TJ, Lu ZH, Wasniowska K, et al. Postcapillary venule endothelial cells in kidney express a multispecific chemokine receptor that is structurally and functionally identical to the erythroid isoform, which is the Duffy blood group antigen. J Clin Invest 1994; 94: 985-91.
48. Peiper SC, Wang ZX, Neote K, et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med 1995; 181: 1311-7.
49. Dawson TC, Lentsch AB, Wang Z, et al. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 2000; 96: 1681-4.
50. Luo H, Chaudhuri A, Zbrzezna V, He Y, Pogo AO. Deletion of the murine Duffy gene (Dfy) reveals that the Duffy receptor is functionally redundant. Mol Cell Biol 2000; 20: 3097-101.
51. Chaudhuri A, Rodriguez M, Zbrzezna V, et al. Induction of Duffy gene (FY) in human endothelial cells and in mouse. Cytokine 2003; 21: 137-48.
52. Hatabu T, Kawazu S, Aikawa M, Kano S. Binding of Plasmodium falciparum-infected erythrocytes to the membrane-bound form of Fractalkine/CX3CL1. Proc Natl Acad Sci USA 2003; 100: 15942-6.
53. Burgmann H, Hollenstein U, Wenisch C, et al. Serum concentrations of MIP-1 alpha and interleukin-8 in patients suffering from acute Plasmodium falciparum malaria. Clin Immunol Immunopathol, 1995; 76: 32-6.
54. Ochiel DO, Awandare GA, Keller CC, et al. Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect Immun 2005; 73: 4190-7.
55. Jaramillo M, Plante I, Ouellet N, et al. Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection. J Immunol 2004; 172: 3101-10.
56. Jaramillo M, Godbout M, Olivier M. Hemozoin induces macrophage chemokine expression through oxidative stress-dependent and -independent mechanisms. J Immunol 2005; 174: 475-84.
57. Sherry BA, Alava G, Tracey KJ, et al. Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo. J Inflamm 1995; 45: 85-96.
58. Chen L, Sendo F. Cytokine and chemokine mRNA expression in neutrophils from CBAN/NS1e mice infected with Plasmodium berghei ANKA that induces experimental cerebral malaria. Parasitol Int 2001; 50: 139-43.
59. Engwerda CR, Beattie L, Amante FH. The importance of the spleen in malaria. Trends Parasitol 2005; 21: 75-90.
60. Grun JL, Long CA, Weidanz WP. Effects of splenectomy on antibody-independent immunity to Plasmodium chabaudi adami malaria. Infect Immun 1985; 48: 853-8.
61. Yadava A, Kumar S, Dvorak JA, Milon G, Miller LH. Trafficking of Plasmodium chabaudi adami-infected erythrocytes within the mouse spleen. Proc Natl Acad Sci USA 1996; 93: 4595-9.
62. Yap GS, Stevenson MM. Differential requirements for an intact spleen in induction and expression of B-cell-dependent immunity to Plasmodium chabaudi AS. Infect Immun 1994; 62: 4219-25.
63. Hauda KM, Sayles PC, Wassom DL. Plasmodium yoelii: cellular immune responses in splenectomized and normal mice. Exp Parasitol 1993; 76: 385-93.
64. Sayles PC, Yanez DM, Wassom DL. Plasmodium yoelii: splenectomy alters the antibody responses of infected mice. Exp Parasitol 1993; 76: 377-84.
65. Favila-Castillo L, Monroy-Ostria A, Kobayashi E, et al. Protection of rats against malaria by a transplanted immune spleen. Parasite Immunol 1996; 18: 325-31.
66. Kumar S, Good MF, Dontfraid F, Vinetz JM, Miller LH. Interdependence of CD4+ T cells and malarial spleen in immunity to Plasmodium vinckei vinckei. Relevance to vaccine development. J Immunol 1989; 143: 2017-23.
67. Sayles PC, Cooley AJ, Wassom DL. A spleen is not necessary to resolve infections with Plasmodium yoelii. Am J Trop Med Hyg 1991; 44: 42-8.
68. Curfs JH, Schetters TP, Hermsen CC, et al. Immunological aspects of cerebral lesions in murine malaria. Clin Exp Immunol 1989; 75: 136-40.
69. Hermsen CC, Mommers E, van de Wiel T, Sauerwein RW, Eling WM. Convulsions due to increased permeability of the blood-brain barrier in experimental cerebral malaria can be prevented by splenectomy or anti-T cell treatment. J Infect Dis 1998; 178: 1225-7.
70. Goodnow CC. Chance encounters and organized rendezvous. Immunol Rev 1997; 156: 5-10.
71. Krucken J, Mehnert LI, Dkhil MA, et al. Massive destruction of malaria-parasitized red blood cells despite spleen closure. Infect Immun 2005; 73: 6390-8.
72. Stevenson MM, Kraal G. Histological changes in the spleen and liver of C57BL/6 and A/J mice during Plasmodium chabaudi AS infection. Exp Mol Pathol 1989; 51: 80-95.
73. Achtman AH, Khan M, MacLennan IC, Langhorne J. Plasmodium chabaudi chabaudi infection in mice induces strong B cell responses and striking but temporary changes in splenic cell distribution. J Immunol 2003; 171: 317-24.
74. Urban BC, Hien TT, Day NP, et al. Fatal Plasmodium falciparum malaria causes specific patterns of splenic architectural disorganization. Infect Immun 2005; 73: 1986-94.
75. Garnica MR, Souto JT, Silva JS, de Andrade HF, Jr. Stromal cell derived factor 1 synthesis by spleen cells in rodent malaria, and the effects of in vivo supplementation of SDF-1alpha and CXCR4 receptor blocker. Immunol Lett 2002; 83: 47-53.
76. Garnica MR, de Moraes LV, Rizzo LV, de Andrade HF, Jr. Supplementation of CXCL12 (CXCL12) induces homing of CD11c+ dendritic cells to the spleen and enhances control of Plasmodium berghei malaria in BALB/c mice. Immunology 2005; 115: 399-406.
77. Sexton AC, Good RT, Hansen DS, et al, Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria. J Infect Dis 2004; 189: 1245-56.
78. Garnica MR, Silva JS, de Andrade Junior HF. Stromal cell-derived factor-1 production by spleen cells is affected by nitric oxide in protective immunity against blood-stage Plasmodium chabaudi CR in C57BL/ 6j mice. Immunol Lett 2003; 89: 133-42.
79. Hanum PS, Hayano M, Kojima S. Cytokine and chemokine responses in a cerebral malaria-susceptible or -resistant strain of mice to Plasmodium berghei ANKA infection: early chemokine expression in the brain. Int Immunol 2003; 15: 633-40.
80. Amichay D, Gazzinelli RT, Karupiah G, et al. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-(gamma) with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol 1996; 157: 4511-20.
81. Weiss L, Geduldig U, Weidanz W. Mechanisms of splenic control of murine malaria: reticular cell activation and the development of a blood-spleen barrier. Am J Anat 1986; 176: 251-85.
82. Looareesuwan S, Suntharasamai P, Webster UK, Ho M. Malaria in splenectomized patients: report of four cases and review. Clin Infect Dis 1993; 16: 361-6.
83. Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002; 185: 1538-41.
84. Wyler DJ, Gallin JI. Spleen-derived mononuclear cell chemotactic factor in malaria infections: a possible mechanism for splenic macrophage accumulation. J Immunol 1977; 118: 478-84.
85. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-90.
86. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989; 142: 1956-62.
87. Wang JM, Sherry B, Fivash MJ, Kelvin DJ, Oppenheim JJ. Human recombinant macrophage inflammatory protein-1 alpha and -beta and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes. J Immunol 1993; 150: 3022-9.
88. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
89. Rudin W, Quesniaux V, Favre N, Bordmann G. Malaria toxins from P. chabaudi chabaudi AS and P. berghei ANKA cause dyserythropoiesis in C57BL/6 mice. Parasitology 1997; 115 (Pt 5): 467-74.
90. Asami M, Owhashi M, Abe T, Nawa Y. A comparative study of the kinetic changes of hemopoietic stem cells in mice infected with lethal and non-lethal malaria. Int J Parasitol 1992; 22: 43-7.
91. Yap GS, Stevenson MM. Inhibition of in vitro erythropoiesis by soluble mediators in Plasmodium chabaudi AS malaria: lack of a major role for interleukin 1, tumor necrosis factor alpha, and gamma interferon. Infect Immun 1994; 62: 357-62.
92. Chang KH, Tam M, Stevenson MM. Inappropriately low reticulocytosis in severe malarial anemia correlates with suppression in the development of late erythroid precursors. Blood 2004; 103: 3727-35.
93. Gibellini D, Bassini A, Re MC, et al. Stroma-derived factor 1alpha induces a selective inhibition of human erythroid development via the functional upregulation of Fas/CD95 ligand. Br J Haematol 2000; 111: 432-40.
94. de Wynter EA, Durig J, Cross MA, Heyworth CM, Testa NG. Differential response of CD34+ cells isolated from cord blood and bone marrow to MIP-1 alpha and the expression of MIP-1 alpha receptors on these immature cells. Stem Cells 1998; 16: 349-56.
95. Su S, Mukaida N, Wang J, et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1alpha by interacting mainly with a C-C chemokine receptor, CCR1. Blood 1997; 90: 605-11.
96. Mitchell AJ, Hansen AM, Hee L, et al. Early cytokine production is associated with protection from murine cerebral malaria. Infect Immun 2005; 73: 5645-53.
97. Hisaeda H, Maekawa Y, Iwakawa D, et al. Escape of malaria parasites from host immunity requires CD4+CD25+ regulatory T cells. Nat Med 2004; 10: 29-30.
98. Hisaeda H, Hamano S, Mitoma-Obata C, et al. Resistance of regulatory T cells to glucocorticoid-induced TNFR family-related protein (GITR) during Plasmodium yoelii infection. Eur J Immunol 2005; 35: 3516-24.
99. Long TT, Nakazawa S, Onizuka S, Huaman MC, Kanbara H. Influence of CD4+CD25+ T cells on Plasmodium berghei NK65 infection in BALB/c mice. Int J Parasitol 2003; 33: 175-83.
100. Walther M, Tongren JE, Andrews L, et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 2005; 23: 287-96.
101. Beeson JG, Duffy PE. The immunology and pathogenesis of malaria during pregnancy. Curr Top Microbiol Immunol 2005; 297: 187-227.
102. Brabin BJ, Romagosa C, Abdelgalil S, et al. The sick placenta-the role of malaria. Placenta 2004; 25: 359-78.
103. Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 2000; 31: 85-93.
104. Galbraith RM, Fox H, Hsi B, et al. The human materno-foetal relationship in malaria. II. Histological, ultrastructural and immunopathological studies of the placenta. Trans R Soc Trop Med Hyg 1980; 74: 61-72.
105. Leopardi O, Naughten W, Salvia L, et al. Malaric placentas. A quantitative study and clinico-pathological correlations. Pathol Res Pract 1996; 192: 892-8.
106. Fried M, Duffy PE. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 1996; 272: 1502-4.
107. Tkachuk AN, Moormann AM, Poore JA, et al. Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J Infect Dis 2001; 183: 967-72.
108. Abrams ET, Brown H, Chensue SW, et al. Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated beta chemokine expression. J Immunol 2003; 170: 2759-64.
109. Suguitan AL Jr, Leke RG, Fouda G, et al. Changes in the levels of chemokines and cytokines in the placentas of women with Plasmodium falciparum malaria. J Infect Dis 2003; 188: 1074-82.
110. Chaisavanceyakorn S, Moore JM, Mirel L, et al. Levels of macrophage inflammatory protein 1 alpha (MIP-1 alpha) and MIP-1 beta in intervillous blood plasma samples from women with placental malaria and human immunodeficiency virus infection. Clin Diagn Lab Immunol 2003; 10: 631-6.
111. Moormann AM, Sullivan AD, Rochford RA, et al. Malaria and pregnancy: placental cytokine expression and its relationship to intrauterine growth retardation. J Infect Dis 1999; 180: 1987-93.
112. Ordi J, Menendez C, Ismail MR, et al. Placental malaria is associated with cell-mediated inflammatory responses with selective absence of natural killer cells. J Infect Dis 2001; 183: 1100-7.
113. Ordi J, Ismail MR, Ventura PJ, et al. Massive chronic intervillositis of the placenta associated with malaria infection. Am J Surg Pathol 1998; 22: 1006-11.
114. Dorman EK, Shulman CE, Kingdom J, et al. Impaired uteroplacental blood flow in pregnancies complicated by falciparum malaria. Ultrasound in Obstetrics and Gynecology 2002; 19: 165-70.
115. Imamura T, Sugiyama T, Cuevas LE, Makunde R, Nakamura S. Expression of tissue factor, the clotting initiator, on macrophages in Plasmodium falciparum-infected placentas. J Infect Dis 2002; 186: 436-40.
116. Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis 2000; 181: 1740-5.
117. Rogerson SJ, Pollina E, Getachew A, et al. Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. Am J Trop Med Hyg 2003; 68: 115-9.
118. Fried M, Muga RO, Misore AO, Duffy PE. Malaria Elicits Type 1 Cytokines in the Human Placenta: IFN-(gamma) and TNF-(alpha) Associated with Pregnancy Outcomes. J Immunol 1998; 160: 2523-30.
119. Drake PM, Red-Horse K, Fisher SJ. Chemokine expression and function at the human maternal-fetal interface. Rev Endocr Metab Disord 2002; 3: 159-65.
120. Fernekorn U, Kruse A. Regulation of leukocyte recruitment to the murine maternal/fetal interface. Chem Immunol Allergy 2005; 89: 105-17.
121. Red-Horse K, Drake PM, Gunn MD, Fisher SJ. Chemokine Ligand and Receptor Expression in the Pregnant Uterus: Reciprocal Patterns in Complementary Cell Subsets Suggest Functional Roles. Am J Pathol 2001; 159: 2199-213.
122. Drake PM, Red-Horse K, Fisher SJ. Reciprocal chemokine receptor and ligand expression in the human placenta: Implications for cytotrophoblast differentiation. Developmental Dynamics 2004; 229: 877-85.
123. Drake PM, Gunn MD, Charo IF, et al. Human Placental Cytotrophoblasts Attract Monocytes and CD56bright Natural Killer Cells via the Actions of Monocyte Inflammatory Protein-1alpha. J Exp Med 2001; 193: 1199-212.
124. Moussa M, Mognetti B, Dubanchet S, et al. Expression of beta chemokines in explants and trophoblasts from early and term human placentae. Am J Reprod Immunol 2001; 46: 309-17.
125. Lockwood CJ, Matta P, Krikun G, et al. Regulation of Monocyte Chemoattractant Protein-1 Expression by Tumor Necrosis Factor (alpha) and Interleukin-1 (beta) in First Trimester Human Decidual Cells: Implications for Preeclampsia. Am J Pathol 2006; 168: 445-52.
126. Steketee RW, Wirima JJ, Hightower AW, et al. The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. Am J Trop Med Hyg 1996; 55: 33-41.
127. Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69: 345-59.
128. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985; 119: 385-401.
129. Toro G, Roman G. Cerebral malaria. A disseminated vasculomyelinopathy. Arch Neurol 1978; 35: 271-5.
130. Ma N, Madigan MC, Chan-Ling T, Hunt NH. Compromised bloodnerve barrier, astrogliosis, and myelin disruption in optic nerves during fatal murine cerebral malaria. Glia 1997; 19: 135-51.
131. Medana IM, Day NP, Hien TT et al. Axonal injury in cerebral malaria. Am J Pathol 2002; 160: 655-66.
132. Medana IM, Mai NT, Day NP, et al. Cellular stress and injury responses in the brains of adult Vietnamese patients with fatal Plasmodium falciparum malaria. Neuropathol Appl Neurobiol 2001; 27: 421-33.
133. Medana IM, Lindert RB, Wurster U, et al. Cerebrospinal fluid levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria. Trans R Soc Trop Med Hyg 2005; 99: 610-7.
134. Berendt AR, Turner GD, Newbold CI. Cerebral malaria: The sequestration hypothesis. Parasitol Today 1994; 10: 412-4.
135. Schofield L, Grau. GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol 2005; 5: 722-35.
136. Clark IA, Rockett KA, Cowden WB. Proposed link between cytokines, nitric oxide and human cerebral malaria. Parasitol Today 1991; 7: 205-7.
137. Clark IA, Rockett KA. The cytokine theory of human cerebral malaria. Parasitol Today 1994; 10: 410-2.
138. Sarfo BY, Singh S, Lillard JW, et al. The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in postmortem tissue samples. Ann Trop Med Parasitol 2004; 98: 297-303.
139. Sarfo BY, Armah HB, Irune I, et al. Plasmodium yoelii 17XL infection up-regulates RANTES, CCR1, CCR3 and CCR5 expression, and induces ultrastructural changes in the cerebellum. Malar J 2005; 4: 63-75.
140. Grau GE, Fajardo LF, Piguet PF, et al. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987; 237: 1210-2.
141. Thurnwood CM, Hunt NH, Clark IA, Cowden WB. Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology 1988; 96: 579-89.
142. Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria? Trends Parasitol 2002; 18: 360-6.
143. Gitau EN, Newton CR. Review Article: Blood-brain barrier in falciparum malaria. Trop Med Int Health 2005; 10: 285-92.
144. Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25: 331-40.
145. Brown H, Rogerson S, Taylor T, et al. Blood-brain barrier function in cerebral malaria in Malawian children. Am J Trop Med Hyg 2001; 64: 207-13.
146. Brown HC, Chau TT, Mai NT, et al. Blood-brain barrier function in cerebral malaria and CNS infections in Vietnam. Neurology 2000; 55: 104-11.
147. Chan-Ling T, Neill AL, Hunt NH. Early microvascular changes in murine cerebral malaria detected in retinal wholemounts. Am J Pathol 1992; 140: 1121-30.
148. Song L, Pachter JS. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res 2004; 67: 78-89.
149. Stamatovic SM, Shakui P, Keep RF, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005; 25: 593-606.
150. Medana IM, Chaudhri G, Chan-Ling T, Hunt NH. Central nervous system in cerebral malaria: 'Innocent bystander' or active participant in the induction of immunopathology? Immunol Cell Biol 2001; 79: 101-20.
151. Medana IM, Chan-Ling T, Hunt NH. Redistribution and degeneration of retinal astrocytes in experimental murine cerebral malaria: relationship to disruption of the blood-retinal barrier. Glia 1996; 16: 51-64.
152. Medana IM, Chan-Ling T, Hunt NH. Reactive changes of retinal microglia during fatal murine cerebral malaria: effects of dexamethasone and experimental permeabilization of the blood-brain barrier. Am J Pathol 2000; 156: 1055-65.
153. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001; 22: 147-84.
154. Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol 1999; 5: 13-26.
155. Nitcheu J, Bonduelle O, Combadiere C, et al. Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol 2003; 170: 2221-8.
156. Ohno T, Kobayashi F, Nishimura M, Fas has a role in cerebral malaria, but not in proliferation or exclusion of the murine parasite in mice. Immunogenetics 2005; 57: 293-6.
157. Potter S, Chaudhri G, Hansen A, Hunt NH. Fas and perforin contribute to the pathogenesis of murine cerebral malaria. Redox Rep 1999; 4: 333-5.
158. Potter S, Chan-Ling T, Ball HJ, et al. Perforin mediated apoptosis of cerebral microvascular endothelial cells during experimental cerebral malaria. Int J Parasitol 2006; 36: 485-96.
159. Potter SM, Chan-Ling T, Rosinova E, et al. A role for Fas-Fas ligand interactions during the late-stage neuropathological processes of experimental cerebral malaria. J Neuroimmunol 2006; 173: 96-107.
160. Pino P, Vouldoukis I, Kolb JP, et al. Plasmodium falciparum-infected erythrocyte adhesion induces caspase activation and apoptosis in human endothelial cells. J Infect Dis 2003; 187: 1283-90.
161. Pino P, Taoufiq Z, Nitcheu J, Vouldoukis I, Mazier D. Blood-brain barrier breakdown during cerebral malaria: suicide or murder? Thromb Haemost 2005; 94: 336-40.
162. Marelli-Berg FM, Jarmin SJ. Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking? Immunol Lett 2004; 93: 109-13.
163. Belnoue E, Kayibanda M, Deschemin JC, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 2003; 101: 4253-9.
164. Belnoue E, Costa FT, Vigario AM, et al. Chemokine Receptor CCR2 Is Not Essential for the Development of Experimental Cerebral Malaria. Infect Immun 2003; 71: 3648-51.
165. Yanez DM, Manning DD, Cooley AJ, Weidanz WP, van der Heyde HC. Participation of lymphocyte subpopulations in the pathogenesis of experimental murine cerebral malaria. J Immunol 1996; 157: 1620-4.
166. Belnoue E, Kayibanda M, Vigario AM, et al. On the pathogenic role of brain-sequestered alphabets CD8+ T cells in experimental cerebral malaria. J Immunol 2002; 169: 6369-75.
167. Pais TF, Chatterjee S. Brain macrophage activation in murine cerebral malaria precedes accumulation of leukocytes and CD8+ T cell proliferation. J Neuroimmunol 2005; 163: 73-83.
168. Bagot S, Nogueira F, Collette A, et al. Comparative study of brain CD8+ T cells induced by sporozoites and those induced by bloodstage Plasmodium berghei ANKA involved in the development of cerebral malaria. Infect Immun 2004; 72: 2817-26.
169. Cook DN, Smithies O, Strieter RM, Frelinger JA, Serody JS. CD8+ T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo. J Immunol 1999; 162: 5423-8.
170. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998; 391: 908-11.
171. Iijima W, Ohtani H, Nakayama T, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003; 163: 261-8.
172. Cho C, Miller RJ. Chemokine receptors and neural function. J Neurovirol 2002; 8: 573-84.
173. Bacon KB, Harrison JK. Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J Neuroimmunol 2000; 104: 92-7.
174. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 2005; 48: 16-42.
175. Glabinski AR, Bielecki B, Kolodziejski P, et al. TNF-(alpha) microinjection upregulates chemokines and chemokine receptors in the central nervous system without inducing leukocyte infiltration. J Interferon Cytokine Res 2003; 23: 457-66.
176. Peterson KE, Errett JS, Wei T, et al. MCP-1 and CCR2 contribute to non-lymphocyte-mediated brain disease induced by Fr98 polytropic retrovirus infection in mice: role for astrocytes in retroviral neuropathogenesis. J Virol 2004; 78: 6449-58.
177. Little AR, Benkovic SA, Miller DB, O'Callaghan JP. Chemically induced neuronal damage and gliosis: enhanced expression of the proinflammatory chemokine, monocyte chemoattractant protein (MCP)-, without a corresponding increase in proinflammatory cytokines. Neuroscience 2002; 115: 307-20.
178. Tani M, Fuentes ME, Peterson JW, et al. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest 1996; 98: 529-39.
179. Huang D, Wujek J, Kidd G, et al. Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. FASEB J 2005; 19: 761-72.
180. Chen SC, Leach MW, Chen Y, et al. Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytes. J Immunol 2002; 168: 1009-17.
181. Tham TN, Lazarini F, Franceschini IA, et al. Developmental pattern of expression of the alpha chemokine stromal cell-derived factor 1 in die rat central nervous system. Eur J Neurosci 2001; 13: 845-56.
182. Tsai HH, Frost E, To V, et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002; 110: 373-83.
183. Luan J, Furuta Y, Du J, Richmond A. Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors. Cytokine 2001; 14: 253-63.
184. Tran PB, Miller RJ. Chemokine receptors in the brain: a developing story. J Comp Neurol 2003; 457: 1-6.
185. van der Meer P, Goldberg SH, Fung KM, et al. Expression pattern of CXCR3, CXCR4, and CCR3 chemokine receptors in the developing human brain. J Neuropathol Exp Neurol 2001; 60: 25-32.
186. Bakhiet M, Tjemlund A, Mousa A, et al. RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat Cell Biol 2001; 3: 150-7.
187. Gillard SE, Lu M, Mastracci RM, Miller RJ. Expression of functional chemokine receptors by rat cerebellar neurons. J Neuroimmunol 2002; 124: 16-28.
188. Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998; 95: 14500-5.
189. Ragozzino D, Giovannelli A, Mileo AM, et al. Modulation of the neurotransmitter release in rat cerebellar neurons by GRO-(beta). Neuroreport 1998; 9: 3601-6.
190. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000; 108: 227-35.
191. Bolin LM, Murray R, Lukacs NW, et al. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 1998; 81: 49-57.
192. Giovannelli A, Limatola C, Ragozzino D, et al. CXC chemokines interleukin-8 (IL-8) and growth-related gene product alpha (GRO-alpha) modulate Purkinje neuron activity in mouse cerebellum. J Neuroimmunol 1998; 92: 122-32.
193. Limatola C, Giovannelli A, Maggi L, et al. SDF-1alpha-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci 2000; 12: 2497-504.
194. van Gassen KL, Netzeband JG, de Graan PN, Gruol DL. The chemokine CCL2 modulates Ca2+ dynamics and electrophysiological properties of cultured cerebellar Purkinje neurons. Eur J Neurosci 2005; 21,:2949-57.
195. Vlkolinsky R, Siggins GR, Campbell IL, Krucker T. Acute exposure to CXC chemokine ligand 10, but not its chronic astroglial production, alters synaptic plasticity in mouse hippocampal slices. J Neuroimmunol 2004; 150: 37-47.
196. Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci USA 2003; 100: 7947-52.
197. Oh SB, Tran PB, Gillard SE, et al. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001; 21: 5027-35.
198. Muessel MJ, Klein RM, Wilson AM, Berman NE. Ablation of the chemokine monocyte chemoattractant protein-1 delays retrograde neuronal degeneration, attenuates microglial activation, and alters expression of cell death molecules. Brain Res Mol Brain Res 2002; 103: 12-27.
199. Kalehua AN, Nagel JE, Whelchel LK et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res 2004; 297: 197-211.
200. Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 2003; 85: 1299-311.
201. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999; 96: 8212-6.
202. Bruno V, Copani A, Besong G, Scoto G, Nicoletti F. Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur J Pharmacol 2000; 399: 117-21.
203. Brenier-Pinchart M-P, Pelloux H, Derouich-Guergour D, Ambroise-Thomas P. Chemokines in host-protozoan-parasite interactions. Trends Parasitol 2001; 17: 292-6.
204. Teixeira MM, Gazzinelli RT, Silva JS. Chemokines, inflammation and Trypanosoma crazi infection. Trends Parasitol 2002; 18: 262-5.
205. Teixeira MJ, Teixeira CR, Andrade BB, Barral-Netto M, Barral A. Chemokines in host-parasiteinteractions in leishmaniasis. Trends Parasitol 2006; 22: 32-40.